Clinical significance and prognostic value of tumor necrosis factor-α and dickkopf related protein-1 in ankylosing spondylitis.
Ankylosing spondylitis
Diagnosis
Dickkopf-related protein-1
Peripheral blood
Prognosis
Tumor necrosis factor-α
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
06 Apr 2020
06 Apr 2020
Historique:
received:
25
12
2019
revised:
02
03
2020
accepted:
19
03
2020
entrez:
28
4
2020
pubmed:
28
4
2020
medline:
28
4
2020
Statut:
ppublish
Résumé
Ankylosing spondylitis (AS) frequently occurs in people aged 30-45 years, and its prevalence is generally believed to be between 0.1% and 1.4% globally. At present, the "gold standard" for diagnosis of AS requires the provision of pelvic X-rays, which makes it more difficult to perform in population-based epidemiological studies. Therefore, the identification of serological indicators related to the diagnosis, treatment, and prognosis of AS patients is of great significance. To analyze the therapeutic, diagnostic significance and prognostic value of dickkopf-related protein-1 (DKK-1) and tumor necrosis factor-α (TNF-α) in AS. A total of 113 patients with active AS were selected as the research group, and 100 healthy subjects who underwent physical examination were selected as the control group. The levels of DKK-1 and TNF-α in peripheral blood in the two groups were compared. The diagnostic and predictive values of DKK-1 and TNF-α for AS were analyzed with ROC curves, and the factors influencing AS recurrence were analyzed with COX regression. Before treatment, the research group showed lower DKK-1 levels but higher TNF-α levels than the control group (both DKK-1 and TNF-α are effective in the diagnosis and treatment of AS and are risk factors for its recurrence. In addition, DKK-1 may be a potential target for the diagnosis of AS.
Sections du résumé
BACKGROUND
BACKGROUND
Ankylosing spondylitis (AS) frequently occurs in people aged 30-45 years, and its prevalence is generally believed to be between 0.1% and 1.4% globally. At present, the "gold standard" for diagnosis of AS requires the provision of pelvic X-rays, which makes it more difficult to perform in population-based epidemiological studies. Therefore, the identification of serological indicators related to the diagnosis, treatment, and prognosis of AS patients is of great significance.
AIM
OBJECTIVE
To analyze the therapeutic, diagnostic significance and prognostic value of dickkopf-related protein-1 (DKK-1) and tumor necrosis factor-α (TNF-α) in AS.
METHODS
METHODS
A total of 113 patients with active AS were selected as the research group, and 100 healthy subjects who underwent physical examination were selected as the control group. The levels of DKK-1 and TNF-α in peripheral blood in the two groups were compared. The diagnostic and predictive values of DKK-1 and TNF-α for AS were analyzed with ROC curves, and the factors influencing AS recurrence were analyzed with COX regression.
RESULTS
RESULTS
Before treatment, the research group showed lower DKK-1 levels but higher TNF-α levels than the control group (both
CONCLUSION
CONCLUSIONS
DKK-1 and TNF-α are effective in the diagnosis and treatment of AS and are risk factors for its recurrence. In addition, DKK-1 may be a potential target for the diagnosis of AS.
Identifiants
pubmed: 32337195
doi: 10.12998/wjcc.v8.i7.1213
pmc: PMC7176625
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1213-1222Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare no conflict of interest.
Références
Arthritis Rheumatol. 2016 Feb;68(2):282-98
pubmed: 26401991
PLoS One. 2018 Apr 24;13(4):e0196281
pubmed: 29689112
Am J Med Sci. 2011 Apr;341(4):284-6
pubmed: 21430444
Clin Chim Acta. 2018 Jun;481:177-183
pubmed: 29544750
Scand J Rheumatol. 2018 Jan;47(1):56-61
pubmed: 28303752
Clin Rheumatol. 2018 Nov;37(11):3093-3098
pubmed: 29995219
Bone. 2006 Oct;39(4):754-66
pubmed: 16730481
J Rheumatol Suppl. 2006 Sep;78:4-11
pubmed: 17042055
Cent Eur J Immunol. 2019;44(1):59-64
pubmed: 31114438
Rheumatology (Oxford). 2014 Apr;53(4):650-7
pubmed: 24324212
Nat Med. 2007 Feb;13(2):156-63
pubmed: 17237793
Curr Rheumatol Rep. 2008 Oct;10(5):371-8
pubmed: 18817640
Bone. 2007 Sep;41(3):331-9
pubmed: 17613296
J Rheumatol. 2016 Dec;43(12):2142-2148
pubmed: 27803139
Rheumatol Int. 2013 Jun;33(6):1409-13
pubmed: 23143621
Clin Rheumatol. 2019 Apr;38(4):989-995
pubmed: 30443790
PLoS One. 2017 Jun 22;12(6):e0177231
pubmed: 28640818
Arthritis Rheum. 2010 Jan;62(1):150-8
pubmed: 20039407
Arthritis Res Ther. 2005;7(3):R439-44
pubmed: 15899030
Ann Rheum Dis. 2017 Mar;76(3):571-592
pubmed: 27582421
Clin Rheumatol. 2007 Feb;26(2):211-5
pubmed: 16583185
Best Pract Res Clin Rheumatol. 2002 Dec;16(5):723-39
pubmed: 12473270
Exp Mol Med. 2016 Apr 22;48:e228
pubmed: 27103566
PLoS One. 2015 Apr 16;10(4):e0122693
pubmed: 25879956